Literature DB >> 29238588

The role of TIPS in the management of liver transplant candidates.

Lukas W Unger1, Theresa Stork1, Theresa Bucsics2, Susanne Rasoul-Rockenschaub1, Katharina Staufer1, Michael Trauner2, Svenja Maschke1, Max Pawloff1, Thomas Soliman1, Thomas Reiberger2, Gabriela A Berlakovich1.   

Abstract

BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) implantation is used for treatment of several complications in patients with liver cirrhosis. Recent studies have identified a survival benefit for patients on the waiting list after TIPS implantation, but the optimal time point for TIPS implantation prior to orthotopic liver transplantation (OLT) has not been established. STUDY: This study retrospectively assessed patients undergoing TIPS implantation before or after listing for OLT at the Medical University of Vienna. n = 98 patients with TIPS on the waiting list between January 1993 and December 2013 were identified (n = 73 (74.5%) pre-listing TIPS, n = 25 (25.5%) post-listing TIPS). A matched control group at the time of OLT without TIPS (n = 60) was included.
RESULTS: More patients with post-listing TIPS (28.0%, 7/25) showed clinical improvement and went off-list than patients with pre-listing TIPS (8.2%, 6/73, p = .0119). A similar proportion of patients with pre-listing TIPS (19.2%, 14/73) and post-listing TIPS (20.0%, 5/25) died on the OLT waiting list. Transplant surgery time was similar in patients with and without TIPS: 348(±13) vs. 337(±10) minutes (p = .5139). Estimated 1-year post-transplant survival was similar across all groups (pre-listing TIPS: 76.2%, post-listing TIPS: 86.0%, no TIPS: 91.2%, log-rank p = .1506).
CONCLUSION: TIPS should be considered in all liver transplant candidates, since it can obviate the need for OLT and optimize bridging to OLT.

Entities:  

Keywords:  Orthotopic liver transplantation; bridge to transplant; portal hypertension; transjugular intrahepatic portosystemic shunt; waiting list

Year:  2017        PMID: 29238588      PMCID: PMC5721983          DOI: 10.1177/2050640617704807

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  23 in total

1.  Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation.

Authors:  Georg P Györi; Gerd R Silberhumer; Sonja Zehetmayer; Barbara Kern; Hubert Hetz; Thomas Soliman; Rudolf Steininger; Ferdinand Mühlbacher; Gabriela A Berlakovich
Journal:  Transpl Int       Date:  2012-07-09       Impact factor: 3.782

2.  New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.

Authors:  Philipp Schwabl; Simona Bota; Petra Salzl; Mattias Mandorfer; Berit A Payer; Arnulf Ferlitsch; Judith Stift; Friedrich Wrba; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger
Journal:  Liver Int       Date:  2014-07-09       Impact factor: 5.828

3.  The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Authors:  Theresa Bucsics; Philipp Schwabl; Mattias Mandorfer; Simona Bota; Wolfgang Sieghart; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Markus Peck-Radosavljevic
Journal:  Liver Int       Date:  2016-06-30       Impact factor: 5.828

4.  Early use of TIPS in patients with cirrhosis and variceal bleeding.

Authors:  Juan Carlos García-Pagán; Karel Caca; Christophe Bureau; Wim Laleman; Beate Appenrodt; Angelo Luca; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Joachim Mössner; Jaime Bosch
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 5.  Management of uninfected and infected ascites in cirrhosis.

Authors:  Elsa Solà; Cristina Solé; Pere Ginès
Journal:  Liver Int       Date:  2016-01       Impact factor: 5.828

6.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

7.  Spleen and Liver Stiffness Is Positively Correlated with the Risk of Esophageal Variceal Bleeding.

Authors:  Matthias Buechter; Alisan Kahraman; Paul Manka; Guido Gerken; Christoph Jochum; Ali Canbay; Alexander Dechêne
Journal:  Digestion       Date:  2016-10-19       Impact factor: 3.216

8.  A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding.

Authors:  G-H Lo; H-L Liang; W-C Chen; M-H Chen; K-H Lai; P-I Hsu; C-K Lin; H-H Chan; H-B Pan
Journal:  Endoscopy       Date:  2007-08       Impact factor: 10.093

9.  Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Authors:  Thomas Reiberger; Arnulf Ferlitsch; Berit A Payer; Mattias Mandorfer; Birgit B Heinisch; Hubert Hayden; Frank Lammert; Michael Trauner; Markus Peck-Radosavljevic; Harald Vogelsang
Journal:  J Hepatol       Date:  2012-12-20       Impact factor: 25.083

10.  Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.

Authors:  Juan Carlos Garcia-Pagán; Marco Di Pascoli; Karel Caca; Wim Laleman; Cristophe Bureau; Beate Appenrodt; Angelo Luca; Alexander Zipprich; Juan G Abraldes; Frederik Nevens; Jean Pierre Vinel; Tilman Sauerbruch; Jaime Bosch
Journal:  J Hepatol       Date:  2012-08-30       Impact factor: 25.083

View more
  2 in total

Review 1.  Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review.

Authors:  Riccardo Inchingolo; Alessandro Posa; Martin Mariappan; Tiago Kojun Tibana; Thiago Franchi Nunes; Stavros Spiliopoulos; Elias Brountzos
Journal:  World J Gastroenterol       Date:  2020-09-14       Impact factor: 5.742

Review 2.  Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis.

Authors:  Nikolaus Pfisterer; Lukas W Unger; Thomas Reiberger
Journal:  World J Hepatol       Date:  2021-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.